Mesothelioma Cancer Centers
Brigham and Women’s Hospital
Doctors Affiliated with this Treatment Facility
Also known as “The Brigham,” Brigham and Women’s Hospital is an internationally recognized leader in the health care and medical research fields. The 793-bed hospital serves as the teaching affiliate of the highly respected Harvard Medical School and is located in the heart of Boston’s medical district. Brigham and Women’s is also a partner in the Dana-Farber/Harvard Cancer Center, a collaboration of 13 separate cancer treatment centers.
Throughout their 180-year history, Brigham and Women’s facilities have consistently been at the forefront of medical advances. In 1847, Boston Lying-In Hospital became the first hospital ever to administer anesthesia during childbirth. In 1923, a doctor at Peter Bent Brigham Hospital performed the world’s first successful heart valve surgery on a 12-year-old girl. The world’s first successful human organ transplant was performed at Peter Bent Brigham in 1954, when a kidney was transplanted from one twin to another – a feat that earned the surgeon a Nobel Prize. In 1984, New England’s first heart transplant was performed at the newly-formed Brigham and Women’s Hospital. And in 2011, a Brigham and Women’s surgical team performed the United States’ first-ever full face transplant.
The Brigham and Women’s Hospital treats mesothelioma cancer at the Lung Center, which is a renowned center of excellence with 36 different programs for respiratory conditions. The hospital is also a founding member of the International Mesothelioma Program (IMP), which is the largest research and treatment effort of its kind across well-renowned medical centers in Boston, in order to extend and improve survival and quality of life for mesothelioma patients. As part of the IMP, Brigham and Women’s Hospital collaborates with the Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Health Care System and Harvard School of Public Health.
The center’s specialists include experts with more than 20 years of experience diagnosing and treating mesothelioma. They provide a team-based approach to treating mesothelioma and their options include chemotherapy, surgery and radiation therapy. As part of the IMP, mesothelioma experts developed the four-gene ratio test, which is a molecular test to help determine patient prognosis from a trimodal therapy plan of those three standard treatments. In utilizing this test, specialists can create more personalized treatment plans with better patient outcomes.
Brigham and Women’s Hospital also offers the latest treatment options to improve prognosis. Their experts utilize their advanced surgical treatments when applicable, like interoperative chemotherapeutic drugs, which are recognized by clinicians around the world. The hospital, along with their IMP collaborators, is leading numerous clinical trials for emerging treatments, including novel biological drugs administered with surgery based on the genetics of a patient’s mesothelioma tumors.
The team at Brigham and Women’s Hospital offers a mesothelioma support team, including social workers and patient liaisons to help simplify the processes beyond treatment itself. Special housing assistance is also offered to mesothelioma patients undergoing treatment and their families.
- Extrapleural Pneumonectomy
- Radiation therapy
- Ranked 20 on 2018–19 U.S. News & World Report Best Hospitals Honor Roll
- Ranked 4 in Adult Cancer Hospitals by U.S. News & World Report
- Commission on Cancer (CoC) accreditation
Mesothelioma Clinical Trials at Brigham and Women’s Hospital
The following clinical trials are in progress or actively recruiting participants at Brigham and Women’s Hospital:
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Conditions: Mesothelioma Last Updated: February 9, 2019 Status: Recruiting
Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.
Conditions: Malignant Pleural Mesothelioma Last Updated: October 12, 2018 Status: Recruiting
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma Last Updated: October 9, 2018 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
Brigham and Women’s Hospital. Mesothelioma.